Bioadaptives, Inc. (BDPT) files notice of late Q2 2026 Form 10-Q

Rhea-AI Filing Summary

Bioadaptives, Inc. filed a notification that its Quarterly Report on Form 10-Q for the period ended June 30, 2026 will be filed late. The company states it needs additional time for compilation and review to ensure adequate disclosure of information required in the report and indicates it expects to file the Form 10-Q within the additional time allowed under Rule 12b-25.

Key Figures

Reporting period: June 30, 2026 Extension period: five calendar days Filing signature date: August 14, 2026 +1 more

4 metrics

Reporting period June 30, 2026 Quarter end date for the delayed Form 10-Q

Extension period five calendar days Maximum delay permitted for a Form 10-Q under Rule 12b-25(b)

Filing signature date August 14, 2026 Date the notification of late filing was signed by the CEO

Contact phone (702) 659-8829 Telephone number provided for James E. Keener

Key Terms

Form 12b-25, unreasonable effort or expense, Section 13 or 15(d), Form 10-Q

4 terms

Form 12b-25 regulatory

"Form 12b-25 | NOTIFICATION OF LATE FILING"

Form 12b-25 is a notice a publicly traded company files with the U.S. Securities and Exchange Commission when it cannot deliver a required periodic report (like a quarterly or annual financial report) on time. It explains the reason for the delay and gives the company a short, temporary window to finish the report without being marked as delinquent; investors watch it because late filings can signal accounting, operational, or control issues that may affect a company’s reliability and stock risk, much like a missed homework deadline can raise concerns about a student’s preparedness.

unreasonable effort or expense regulatory

"could not be filed without unreasonable effort or expense"

Section 13 or 15(d) regulatory

"reports required under Section 13 or 15(d) of the Securities Exchange Act"

Form 10-Q financial

"Quarterly Report on Form 10-Q for the period ended June 30, 2026"

A Form 10-Q is a detailed report that publicly traded companies are required to file with regulators three times a year, providing an update on their financial health and business activities. It is important for investors because it offers timely insights into a company's performance, helping them make informed decisions about buying or selling stocks. Think of it as a regular check-up report that shows how well a company is doing.

FAQ

Why did Bioadaptives, Inc. (BDPT) file an NT 10-Q?

Bioadaptives, Inc. filed an NT 10-Q because its Form 10-Q for the period ended June 30, 2026 could not be completed on time. The company cites a need for additional compilation and review to ensure adequate disclosure of required information.

When does Bioadaptives, Inc. (BDPT) expect to file the delayed Form 10-Q?

Bioadaptives, Inc. states it fully expects to file its delayed Form 10-Q within the additional time allowed under Rule 12b-25. For a quarterly report, this extension is up to five calendar days after the original due date.

Which reporting period is covered by the late Form 10-Q for BDPT?

The late Form 10-Q for Bioadaptives, Inc. covers the quarter ended June 30, 2026. The company indicates the delay relates specifically to this period and the associated disclosures required in that quarterly report.

What reason did BDPT give for needing more time to file its 10-Q?

Bioadaptives, Inc. explains that it requires additional time for compilation and review to ensure adequate disclosure of certain information. The company indicates this work could not be completed within the prescribed time period.

Who signed the NT 10-Q filing for Bioadaptives, Inc. (BDPT)?

The NT 10-Q notification was signed on August 14, 2026 by James E. Keener, CEO of Bioadaptives, Inc. His listed contact telephone number is (702) 659-8829 for further information.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/14/2026 - 05:25 PM Accepted by SEC EDGAR 08/14/2026 - 05:25 PM Learn about SEC filing dates

		OMB APPROVAL
	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549	OMB Number: 3235-0058 Expires: April 30, 2025 Estimated average burden hours per response................. 2.50
	FORM 12b-25	SEC FILE NUMBER
	NOTIFICATION OF LATE FILING	CUSIP NUMBER

(Check one):	☐ Form 10-K	☐ Form 20-F	☐ Form 11-K
	☒ Form 10-Q	☐ Form 10-D	☐ Form N-CEN	☐ Form N-CSR

For Period Ended: June 30, 2026

☐ Transition Report on Form 10-K

☐ Transition Report on Form 20-F

☐ Transition Report on Form 11-K

☐ Transition Report on Form 10-Q

For the Transition Period Ended: ________________________________

Read Instruction (on back page) Before Preparing Form. Please Print or Type.

Nothing in this Form shall be construed to imply that the Commission has verified any information contained herein.

If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates: ____________________

PART I - REGISTRANT INFORMATION

BIOADAPTIVES, INC.

Full Name of Registrant

Former Name if Applicable

2620 Regatta Drive, Suite 102

Address of Principal Executive Office (Street and Number)

Las Vegas, Nevada 89128

City, State and Zip Code

SEC 1344 (06-19) Potential persons who are to respond to the collection of information contained in this Form are not required to respond unless the Form displays a currently valid OMB control number.

PART II-RULES 12b-25(b) AND (c)

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

☒	(a)	The reason described in reasonable detail in Part III of this Form could not be eliminated without unreasonable effort or expense;
☒	(b)	The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on  or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
	(c)	The accountant's statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

PART III - NARRATIVE

State below in reasonable detail why Forms 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

The Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2026 cannot be filed within the prescribed time period, because the Company requires additional time for compilation and review to ensure adequate disclosure of certain information required to be included in the Form 10-Q. The Company fully expects to be able to file within the additional time allowed.

PART IV - OTHER INFORMATION

(1) Name and telephone number of person to contact in regard to this notification

James E Keener		(702)		659-8829
(Name)		(Area Code)		(Telephone Number)

(2)	Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s). ☒ Yes    ☐ No
(3)	Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? ☐ Yes    ☒ No
	If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

2 of 3

BIOADAPTIVES, INC.

(Name of Registrant as Specified in Charter)

has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

Date: August 14, 2026	By:	/s/ James E Keener
		James E Keener, CEO

3 of 3